Viva Biotech is the fourth largest company in China’s drug discovery services industry, with a 2.6 per cent market share. Photo: Bloomberg
Investors pile into Viva Biotech’s Hong Kong IPO as they are confident of the R&D services provider’s business model
- Not only is the firm profit-making, but its investment in potential drug candidates has made it attractive to investors, says Louis Tse Ming Kwong of VC Asset Management
- Viva’s business model of taking equity in smaller companies is a convenient way of having many shots on a goal in the Asian biotech, says Brad Loncar of Loncar Investments
Topic |
Health & Fitness
Viva Biotech is the fourth largest company in China’s drug discovery services industry, with a 2.6 per cent market share. Photo: Bloomberg